Financial calendar for 2007
Innate Pharma SA announces its tentative financial and investor relations calendar for 2007 as well as the start of its web-base investor documentation centre.
Financials and Corporate
Innate Pharma announces the full exercise of the greenshoe in the context of its initial public offering (IPO) on the Eurolist market (Compartment C) of Euronext Paris
Innate Pharma SA, a biopharmaceutical company specialising in immunology and developing first-in-class* drugs targeting the innate immune system, announces the full exercise of the over-allotment...
Innate Pharma announces the success of its initial public offering (IPO) on the Eurolist market (Compartment C) of Euronext Paris
Demand from institutional investors was 2.5 times the number of shares offered
Innate Pharma SA announces the details of its initial public offering on the Eurolist market at Euronext Paris
The offer price is set at €4.50 per share.
Launch of Innate Pharma's IPO on Eurolist C by Euronext in Paris
Price range: between 4.15 € and 4.80 € per share.
Registration of French "Document de base" with the AMF
Innate Pharma S.A. announces the registration of its French Document de Base with the AMF in the context of its contemplated IPO on the Eurolist by Euronext TM Paris.
Financial results for the first half of 2006
Innate Pharma S.A. announced today its results for the six months ended June 30, 2006.
Strategic partnership with Novo Nordisk to research and develop drugs targeting NK
Innate Pharma and Novo Nordisk announce strategic partnership to research and develop drugs targeting natural killer cells.
Number of shares and voting rights, as of December 31, 2007
Innate Pharma SA has released the total number of shares outstanding and voting rights, as of December 31, 2007.
Operating revenue of 14.2 million euros in 2007
Innate Pharma SA announces an operating revenue of 14.2 million euros in 2007. Turnover for the year amounted to 8.7 million euros, including 3.6 million euros in the fourth quarter ended December 31...